Cargando…

Macitentan: entry-into-humans study with a new endothelin receptor antagonist

PURPOSE: To study the pharmacokinetics, pharmacodynamics, and tolerability of rising single doses of macitentan, an endothelin receptor antagonist, in healthy male subjects. METHODS: This double-blind, placebo-controlled study was performed in seven groups of eight healthy male subjects. Doses of 0....

Descripción completa

Detalles Bibliográficos
Autores principales:	Sidharta, Patricia N., van Giersbergen, Paul L. M., Halabi, Atef, Dingemanse, Jasper
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2011
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3169777/ https://www.ncbi.nlm.nih.gov/pubmed/21541781 http://dx.doi.org/10.1007/s00228-011-1043-2

Ejemplares similares

Clinical Pharmacokinetics and Pharmacodynamics of the Endothelin Receptor Antagonist Macitentan
por: Sidharta, P. N., et al.
Publicado: (2015)

Effect of Cyclosporine and Rifampin on the Pharmacokinetics of Macitentan, a Tissue-Targeting Dual Endothelin Receptor Antagonist
por: Bruderer, Shirin, et al.
Publicado: (2011)

Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment
por: Fontes, Magda S. C., et al.
Publicado: (2022)

The Endothelin Receptor Antagonist Macitentan Inhibits Human Cytomegalovirus Infection
por: Landázuri, Natalia, et al.
Publicado: (2021)

Pulmonary arterial hypertension outcomes upon endothelin-1 receptor antagonist switch to macitentan
por: Tynan, Timothy, et al.
Publicado: (2019)

Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects
por: Sidharta, Patricia N, et al.
Publicado: (2019)

Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience
por: Belge, Catharina, et al.
Publicado: (2019)

Effects of the Dual Endothelin Receptor Antagonist Aprocitentan on Body Weight and Fluid Homeostasis in Healthy Subjects on a High Sodium Diet
por: Gueneau de Mussy, Pierre, et al.
Publicado: (2020)

Efficacy and safety of the endothelin-1 receptor antagonist macitentan in epicardial and microvascular vasospasm; a proof-of-concept study
por: Feenstra, Rutger G.T., et al.
Publicado: (2023)

Slow Receptor Dissociation Kinetics Differentiate Macitentan from Other Endothelin Receptor Antagonists in Pulmonary Arterial Smooth Muscle Cells
por: Gatfield, John, et al.
Publicado: (2012)

Macitentan, a double antagonist of endothelin receptors, efficiently impairs migration and microenvironmental survival signals in chronic lymphocytic leukemia
por: Maffei, Rossana, et al.
Publicado: (2017)

Evaluation of the Endothelin Receptor Antagonists Ambrisentan, Bosentan, Macitentan, and Sitaxsentan as Hepatobiliary Transporter Inhibitors and Substrates in Sandwich-Cultured Human Hepatocytes
por: Lepist, Eve-Irene, et al.
Publicado: (2014)

Macitentan in pulmonary arterial hypertension: The SERAPHIN trial
por: Said, Karim
Publicado: (2014)

SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2017)

Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of the P2Y12 receptor antagonist selatogrel
por: Schilling, Uta, et al.
Publicado: (2022)

Clinical Pharmacology of Clazosentan, a Selective Endothelin A Receptor Antagonist for the Prevention and Treatment of aSAH-Related Cerebral Vasospasm
por: Juif, Pierre-Eric, et al.
Publicado: (2021)

The endothelin receptor antagonist macitentan for the treatment of pulmonary arterial hypertension: A cross‐species comparison of its cytochrome P450 induction pattern
por: Treiber, Alexander, et al.
Publicado: (2020)

The Endothelin Receptor Antagonist Macitentan Improves Isosorbide-5-Mononitrate (ISMN) and Isosorbide Dinitrate (ISDN) Induced Endothelial Dysfunction, Oxidative Stress, and Vascular Inflammation
por: Steven, Sebastian, et al.
Publicado: (2018)

Endothelin Receptors and Their Antagonists()()
por: Maguire, Janet J., et al.
Publicado: (2015)

Inhibiting Endothelin Receptors with Macitentan Strengthens the Bone Protective Action of RANKL Inhibition and Reduces Metastatic Dissemination in Osteosarcoma
por: Muñoz-Garcia, Javier, et al.
Publicado: (2022)

Endothelin Receptor Antagonists in Kidney Disease
por: Martínez-Díaz, Irene, et al.
Publicado: (2023)

Orexin Receptor Antagonism, a New Sleep-Enabling Paradigm: A Proof-of-Concept Clinical Trial
por: Hoever, P, et al.
Publicado: (2012)

Relative bioavailability of a pediatric dispersible tablet and adult film‐coated tablet of macitentan in healthy volunteers
por: Sidharta, Patricia N., et al.
Publicado: (2020)

Bradykinin 1 Receptor Antagonist BI1026706 Does Not Reduce Central Retinal Thickness in Center-Involved Diabetic Macular Edema
por: Lang, Gabriele E., et al.
Publicado: (2020)

Activity of preclinical and phase I clinical trial of a novel androgen receptor antagonist GT0918 in metastatic breast cancer
por: Li, Huiping, et al.
Publicado: (2021)

The effect of mild and moderate renal impairment on the pharmacokinetics of pridopidine, a new drug for Huntington's disease
por: Rabinovich‐Guilatt, L., et al.
Publicado: (2015)

Bioequivalence of macitentan and tadalafil given as fixed‐dose combination or single‐component tablets in healthy subjects
por: Grill, Simon, et al.
Publicado: (2020)

The Role of Endothelin-1 and Endothelin Receptor Antagonists in Inflammatory Response and Sepsis
por: Kowalczyk, Agata, et al.
Publicado: (2014)

Antidiuretic Effects of the Endothelin Receptor Antagonist Avosentan
por: Baltatu, Ovidiu Constantin, et al.
Publicado: (2012)

Iontophoresis of Endothelin Receptor Antagonists in Rats and Men
por: Roustit, Matthieu, et al.
Publicado: (2012)

Evidence for biased agonists and antagonists at the endothelin receptors
por: Maguire, Janet J.
Publicado: (2016)

Endothelin and Endothelin Antagonists in Chronic Kidney Disease
por: Kohan, Donald E., et al.
Publicado: (2014)

An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN-D0501 in healthy subjects
por: Round, Patrick, et al.
Publicado: (2011)

Absorption, Metabolism, and Excretion of ACT-1004-1239, a First-In-Class CXCR7 Antagonist: In Vitro, Preclinical, and Clinical Data
por: Huynh, Christine, et al.
Publicado: (2022)

Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer
por: Agarwal, Neeraj, et al.
Publicado: (2016)

Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment
por: Berger, Benjamin, et al.
Publicado: (2021)

Endothelin antagonists: new bullets against lung injury?
por: Leeman, Marc
Publicado: (2005)

Endothelin-receptor antagonists are proapoptotic and antiproliferative in human colon cancer cells
por: Peduto Eberl, L, et al.
Publicado: (2003)

Assessment of Target Engagement in a First‐in‐Human Trial with Sinbaglustat, an Iminosugar to Treat Lysosomal Storage Disorders
por: Gehin, Martine, et al.
Publicado: (2020)

Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases
por: Albach, Fredrik N., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7kc1a9j2t65au3d6dc9gp0ckcl